Gameto develops stem cell-derived therapies for reproductive longevity, led by Fertilo, which matures eggs outside the body for IVF using engineered ovarian support cells. It raised a $44 million Series C in August 2025, taking total funding to $127 million.
At a glance
| Price from | Custom |
| Best for | Fertility clinics and women's health partners |
From Gameto's own website.
What stands out
- Pivotal Phase 3 trial under way
- Shortens hormone stimulation for IVF
Worth knowing
- Not yet approved in the US
- Reproductive ageing only
How it ranks
Gameto is ranked 10th of 10 in Best Longevity Startups (Lister Score 85.0).
#10 in Best Longevity Startups · Lister Score 85.0
Gameto says Fertilo is the first therapy made from induced pluripotent stem cells to reach late-stage clinical development in the US..
| Rank | Best Longevity Startups | Score |
|---|---|---|
| 1 | Altos Labs | 96.8 |
| 2 | NewLimit | 95.6 |
| 3 | Retro Biosciences | 94.3 |
| 4 | Loyal | 93.1 |
| 5 | Function Health | 91.8 |
| 6 | Life Biosciences | 90.4 |
| 7 | Juvenescence | 89.1 |
| 8 | Rubedo Life Sciences | 87.7 |
| 9 | Cambrian Bio | 86.4 |
| 10 | Gameto | 85.0 |
Frequently asked questions
How does Gameto rank on Lister?
Gameto is ranked 10th of 10 in Best Longevity Startups (Lister Score 85.0).
Appears in
Add this badge to your site
If you work at Gameto, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.